Added to YB: 2026-09-15
Pitch date: 2026-09-11
VNDA [neutral]
Vanda Pharmaceuticals Inc.
+0.59%
current return
Author Info
No bio for this author
Company Info
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Market Cap
$307.8M
Pitch Price
$5.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.92
P/E
-1.10
EV/Sales
0.74
Sector
Biotechnology
Category
growth
Biotech Conference coverage day 4 session 1 - Vanda Pharmaceuticals Inc.
VNDA (quick overview): Vanda is expanding beyond its three-product base, with approved Basanti expected to launch by year-end and Nereus offering the largest upside through Phase 3 results in GLP-1-associated nausea and vomiting. At roughly $5.04, the stock could offer meaningful upside if the GLP-1 indication succeeds, but the case hinges on transitioning about 10,000 FinAPT patients without material payer disruption; management’s $750M 2030 psychiatry target also requires several unproven events.
Read full article (2 min)